Marjolein Spiering

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study

Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., 31 Mar 2019, In: Haematologica. 104, 4, p. e151-e153

Research output: Contribution to journal › Letter › Academic › peer-review

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

JULIET Investigators, Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., & 18 othersAwasthi, R., Chu, J., Anak, Ö., Salles, G., Maziarz, R. T., Study group members AMC, Kersten, M. J. J., Biemond, B. J., Burger, P., Claessen, M-J. J. A. G., Hazenberg, M. D., Kater, A. P., Kemper, E. M., Nur, E., Spiering, M., Tonino, S. H., Voermans, C. & Zeerleder, S. S., 3 Jan 2019, In: New England journal of medicine. 380, 1, p. 45-56 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K. & Kersten, M. J., 2018, In: Blood Cancer Journal. 8, 2, p. 16 16.

Research output: Contribution to journal › Comment/Letter to the editor › Academic